Oral Cancer Detection Increased with Saliva Test
|
By LabMedica International staff writers Posted on 10 May 2012 |
A simple saliva test has been created which could identify the presence of biomarkers that are associated with oral cancer.
The easy, cost-effective saliva test to detect oral cancer would be a breakthrough that would drastically improve screening and result in fewer people dying of the world's sixth most common cancer.
A surgical team at Michigan State University (East Lansing, MI, USA) is teaming up with a local area dental benefits firm for a clinical trial of the saliva test that will aid physicians and dentists to know which patients need treatment and which ones could avoid needless and invasive biopsies. The scientists will be looking for certain biomarkers previously identified by researchers at the University of California (UCLA; Los Angeles, CA, USA). The biomarkers have been shown in studies to confirm the presence of oral cancer.
Barry Lloyd Wenig, MD, MPH, PhD, a professor of otolaryngology and lead investigator said, "Most white lesions are benign, so a majority of people who develop them are getting biopsies that are not needed. Conversely, a simple test would allow us to identify those patients with malignant lesions and get them into treatment quicker. These tests are as noninvasive as it gets; patients simply need to spit into a cup. The ease of the test will greatly expand our ability to effectively screen for the cancerous lesions. Right now, there are no early screenings available for most head and neck cancers."
Prof. Wenig is teaming up with Delta Dental (Okemos, MI, USA) which works with scientists from leading universities to monitor advances in science. Their chief science officer, Jed J. Jacobson, DDS, MPH, said, "The results of this trial could be life changing for many people. It is a tremendous opportunity for the dental community to participate in what could be a groundbreaking project.” Oral cancer has a poor survival rate linked to late detection; only 60% of patients live beyond five years after diagnosis. The survival rate is less than 38% among black males.
Related Links:
Michigan State University
University of California
Delta Dental
The easy, cost-effective saliva test to detect oral cancer would be a breakthrough that would drastically improve screening and result in fewer people dying of the world's sixth most common cancer.
A surgical team at Michigan State University (East Lansing, MI, USA) is teaming up with a local area dental benefits firm for a clinical trial of the saliva test that will aid physicians and dentists to know which patients need treatment and which ones could avoid needless and invasive biopsies. The scientists will be looking for certain biomarkers previously identified by researchers at the University of California (UCLA; Los Angeles, CA, USA). The biomarkers have been shown in studies to confirm the presence of oral cancer.
Barry Lloyd Wenig, MD, MPH, PhD, a professor of otolaryngology and lead investigator said, "Most white lesions are benign, so a majority of people who develop them are getting biopsies that are not needed. Conversely, a simple test would allow us to identify those patients with malignant lesions and get them into treatment quicker. These tests are as noninvasive as it gets; patients simply need to spit into a cup. The ease of the test will greatly expand our ability to effectively screen for the cancerous lesions. Right now, there are no early screenings available for most head and neck cancers."
Prof. Wenig is teaming up with Delta Dental (Okemos, MI, USA) which works with scientists from leading universities to monitor advances in science. Their chief science officer, Jed J. Jacobson, DDS, MPH, said, "The results of this trial could be life changing for many people. It is a tremendous opportunity for the dental community to participate in what could be a groundbreaking project.” Oral cancer has a poor survival rate linked to late detection; only 60% of patients live beyond five years after diagnosis. The survival rate is less than 38% among black males.
Related Links:
Michigan State University
University of California
Delta Dental
Latest Pathology News
- Pathogen-Agnostic Testing Reveals Hidden Respiratory Threats in Negative Samples
- Molecular Imaging to Reduce Need for Melanoma Biopsies
- Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
- AI-Powered 3D Scanning System Speeds Cancer Screening
- Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
- New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
- AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
- High-Resolution Cancer Virus Imaging Uncovers Potential Therapeutic Targets
- Research Consortium Harnesses AI and Spatial Biology to Advance Cancer Discovery
- AI Tool Helps See How Cells Work Together Inside Diseased Tissue
- AI-Powered Microscope Diagnoses Malaria in Blood Smears Within Minutes
- Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
- First-Of-Its-Kind Test Identifies Autism Risk at Birth
- AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
- Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
- Fast Label-Free Method Identifies Aggressive Cancer Cells
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreMolecular Diagnostics
view channel
New Blood Test Can Help Predict Testicular Cancer Recurrence
Stage 1 testicular germ cell tumor is typically treated with surgery followed by active surveillance. Although most patients experience strong long-term outcomes, about one in four will see their cancer... Read more
New Test Detects Alzheimer’s by Analyzing Altered Protein Shapes in Blood
Alzheimer’s disease begins developing years before memory loss or other symptoms become visible. Misfolded proteins gradually accumulate in the brain, disrupting normal cellular processes.... Read more
New Diagnostic Markers for Multiple Sclerosis Discovered in Cerebrospinal Fluid
Multiple sclerosis (MS) affects nearly three million people worldwide and can cause symptoms such as numbness, visual disturbances, fatigue, and neurological disability. Diagnosing the disease can be challenging... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read moreMicrobiology
view channel
Rapid Sequencing Could Transform Tuberculosis Care
Tuberculosis remains the world’s leading cause of death from a single infectious agent, responsible for more than one million deaths each year. Diagnosing and monitoring the disease can be slow because... Read more
Blood-Based Viral Signature Identified in Crohn’s Disease
Crohn’s disease is a chronic inflammatory intestinal disorder affecting approximately 0.4% of the European population, with symptoms and progression that vary widely. Although viral components of the microbiome... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







